NovaBridge Biosciences (NBP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.82
- As of
Kresmion compiles this page from NBP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
NovaBridge Biosciences (NBP): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-28.
See the full NBP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NBP on one page. Preview it with sample data, then open it live with a free account.
Preview the NBP dossierActive events for NBP
- high13F: funds added
4 tracked funds increased NBP this 2026Q2, institutional consensus
- high13F: funds added
3 tracked funds increased NBP this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +1477% to NBP (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +178% to NBP (2026Q2)
- medium13F: new position
TWO SIGMA INVESTMENTS, LP new position in NBP
FREE, NO ACCOUNT
Every event on NBP, as it fires
You are seeing 5 of 12 events recorded on NBP since 2026-06-09.
The five above landed across 2 days. The other 7 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
NBP positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 44975P103 · 2026Q3 | $662K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NBP
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
More data on NBP
NBP against its peers
NBP's operating margin of -14916.0% ranks in the 14th percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-01-31 and 2025-12-31.
| Metric | NBP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 632000 USD | 30.9M USD | 21 | 11 |
| Operating margin | -14916.0% | -168.5% | 14 | 10 |
| Net margin | -7321.0% | -161.1% | 14 | 10 |
| Return on equity | -20.0% | -74.2% | 81 | 17 |
| 1 year | -82.5% | -22.9% | 7 | 22 |
Peers (23): ORGO, EQ, VYGR, OKUR, ANIX, NRXP, UNCY, MOLN, NERV, ADAG, PMVP, ENGN, VANI, ICCC, TVGN, CLLS, IMUX, ZURA, BETRF, INO, VXRT, PYPD, FHTX. Left out: OTLK (no annual filing), RTSN (no annual filing). Fiscal periods ending between 2025-01-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NBP: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in NBP on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on NBP in the last 180 days.
Upstream: SEC EDGAR filings for NBP
Kresmion, "NovaBridge Biosciences (NBP) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/NBP. Upstream data: SEC EDGAR filings for NBP.
Link to this data (HTML):
<a href="https://kresmion.com/research/NBP">NovaBridge Biosciences (NBP) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow NBP on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to NBP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.